#DEST chief executive Neil Clark talks us through the publication of new data on NTCD-M3, its novel treatment for the prevention of C. difficile
infection (CDI) recurrence, in the peer reviewed journal Public Library of Science One. C.difficile
is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year, with many of these initial cases recurring leading to 29,000 deaths per year and costing the healthcare industry billions of dollars.
The study - carried out by Destiny's scientific adviser Professor Dale Gerding and his team at the VA Hines laboratories in the US - offers further validation of the potential of the biotherapeutic ahead of planned Phase 3 clinical trials of NTCD-M3 in 2023 having previously reported very good Phase 2 clinical trial results.
Destiny is currently finalising preparations for thel trial and seeking partners to help co-fund studies and lead commercialisation of this exciting biotherapeutic product. To read the full RNS click here